GE HealthCare Technologies Inc. (NASDAQ: GEHC)

GE HealthCare Technologies Inc. is a leading global healthcare solutions provider specializing in advanced medical technology, pharmaceutical diagnostics, and AI, cloud, and software solutions. The company serves clinicians and healthcare systems with innovative products designed to tackle complex diseases and improve patient care. With a history spanning nearly 130 years, GE HealthCare delivers bold innovations aimed at the next era of medicine, focusing on personalized and precise patient care. The company's operations are supported by a robust operational culture, driven by its lean business system, Heartbeat, and a commitment to quality and integrity.

GE HealthCare generates revenue through the sale of medical devices, consumable products, service capabilities, and AI-enabled cloud and software solutions. The company's extensive portfolio includes products like molecular imaging systems, computed tomography scanners, magnetic resonance imaging machines, women's health products, and X-ray systems. Additionally, GE HealthCare offers advanced visualization solutions, patient care solutions, and pharmaceutical diagnostics. The customer base comprises hospitals, health systems, and researchers, including public, private, academic, and government institutions. These solutions address significant healthcare challenges, aiming to advance care delivery, reduce disease burden, enable better patient outcomes, and drive sustainable growth.

• Imaging: This segment includes five product lines: Molecular Imaging (MI), Computed Tomography (CT), Magnetic Resonance (MR), Women's Health, and X-ray. The MI/CT product lines encompass cyclotrons, chemistry synthesis, positron emission tomography (PET), computed tomography (PET/CT), single-photon emission computed tomography (SPECT), PET/MR, and nuclear medicine systems. The Women's Health and X-ray product lines offer imaging and biopsy positioning systems for breast cancer screening and diagnosis, as well as dual energy X-ray absorptiometry scanners for bone and metabolic diseases. The segment also provides a suite of AI-enabled software and applications to improve productivity and patient outcomes.

• Advanced Visualization Solutions (AVS): The AVS segment is focused on designing solutions aligned by specialties or care areas for specific clinical workflows. It includes Comprehensive Care Ultrasound, Women's Health Ultrasound, CardioVascular and Interventional Solutions, and Surgical Innovations. Comprehensive Care Ultrasound systems produce images for precise screening, diagnosis, monitoring, and treatment across various applications. Women's Health Ultrasound provides systems for obstetrics, gynecology, and assisted reproductive medicine. CardioVascular and Interventional Solutions offer innovative solutions for cardiology, peripheral vascular, neurology, and oncology. Surgical Innovations products include advanced mobile surgical C-arms for surgical imaging and visualization technology for real-time information during surgical procedures.

• Patient Care Solutions (PCS): The PCS segment serves care teams and healthcare systems across multiple patient care needs, including Monitoring Solutions and Life Support Solutions. Monitoring Solutions include Patient Monitoring and Diagnostic Cardiology, offering comprehensive multi-parameter monitors, central stations, continuous, wearable, and mobile monitors, transport monitors, cardiac telemetry solutions, and visualization, alarm distribution, and care team collaboration solutions. Diagnostic Cardiology provides electrocardiogram (ECG) solutions for detecting cardiovascular disease. Life Support Solutions include Maternal Infant Care and Anesthesia, offering products for labor and delivery departments and neonatal intensive care units, as well as life support solutions via ventilation technology for surgeries. The segment also includes a Consumables portfolio and Digital Solutions for clinical decision support in acute and other care settings.

• Pharmaceutical Diagnostics (PDx): The PDx segment supplies contrast and radiopharmaceutical imaging agents to the global radiology and nuclear medicine industries. These agents help clinicians assess patients for more precise diagnoses, monitor disease progression, and enable better therapy selection. The segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals. Contrast media are used to increase the visibility of tissues or structures in imaging exams, while radiopharmaceuticals work by accumulating in areas of diagnostic interest and emitting energy detected by SPECT or PET scanners.

GE HealthCare operates in a highly competitive global medical technology industry, facing a wide variety of competitors, including Siemens Healthineers, Philips Healthcare, United Imaging, Mindray, and Canon. In the PDx business segment, the company primarily competes with Bayer, Bracco, Guerbet, and Curium. Key competitive factors include value, quality and performance, safety, delivery speed, service and support, technology and innovation, software offering, and brand reputation. The company's competitive advantages lie in its extensive portfolio of solutions, strong operational culture, and commitment to quality and integrity.

The company's customer base includes hospitals, health systems, and researchers, encompassing public, private, academic, and government institutions. GE HealthCare's solutions are designed to address the biggest challenges facing healthcare today, fostering trust, loyalty, and partnership with its global customer base. The company's reach into top hospitals and health systems is evidenced by its long-standing collaborations with leading institutions around the world.